Agios Pharmaceuticals Inc., the sponsor of two drugs that may change the outcomes for a subset of acute myelogenous leukemia patients, is focused on more than AML.
As the landscape in acute myelogenous leukemia changes, consultations with top-tier experts have become a necessity, said John Byrd, the principal investigator of Beat AML, Distinguished University Professor, the D. Warren Brown Professor of Leukemia Research at The Ohio State University, a member of the NCI Leukemia Steering Committee, chair of the Leukemia and Correlative Science Committee within the Alliance for Clinical Trials in Oncology.
As a veteran of the FDA Oncologic Drugs Advisory Committee, Maha Hussain took part in the group's past discussions on treatment options for men with non-metastatic castration-resistant prostate cancer.
The endpoint of metastasis-free survival is unlikely to be used in settings beyond non-metastatic castration-resistant prostate cancer, said Julia Beaver, director of Division of Oncology Products 1 at the FDA Center for Drug Evaluation and Research.
The two FDA pilot programs—Real-Time Oncology Review and Assessment Aid sped up the processing of Novartis's supplemental new drug applications for Kisqali (ribociclib), said Samit Hirawat, executive vice president and head of Global Oncology at Novartis.
After achieving complete regression in several patients with different solid tumor types, Steven Rosenberg is eyeing the biggest prize imaginable—advancing the therapies he has championed for over four decades into the clinic as treatments for commonly occurring cancers.
In 2010, Otis Brawley and I were in the midst of writing a book about the state of cancer care in America.
I have been following Vinay Prasad's work for several years, agreeing with some of what he said, but never quite finding time to look carefully at his argumentation.
The practice-changing TAILORx trial was brought to you by publicly funded cancer clinical trials system, pointing to its continuing relevance, said Jeff Abrams, NCI acting director for clinical research and associate director of the Cancer Therapy Evaluation Program.
Patients who come to the American University of Beirut Medical Center and the Children's Cancer Center of Lebanon now have the same chances of cure, thanks to systematic program building over the years, said Raya Saab, acting director of the Children's Cancer Institute, and director of the Pediatric Cancer Research Program at the American University of Beirut Medical Center.
